Meneldor

INTRODUCTION Meneldor offers her customers the unique opportunity to co-invest alongside specialists, in exciting early stage Biotech and Pharma companies. A sector often considered as very risky and highly complex. Meneldor thoroughly studies the science behind her potential portfolio companies. If the science is sound, then all other key aspects; IP, medical need, addressable markets, competition, risk, management, financial needs, valuation, etc., are assessed. Only if a target company meets our selection criteria, Meneldor will invest and invite her co-investors to participate. INVESTMENT FOCUS Meneldor focuses on early stage biotech and pharma companies that (re)develop (New) Bio or Chemical Molecular Entities, that have outstanding technology with strong IP, address significant unmet medical needs and attractive markets. We are especially scouting for companies that work on relatively low risk and high growth opportunities. We mainly invest in projects which are in preclinical, Phase I or Phase II and in indications with preferably clear well defined clinical endpoints. Our geographic focus is Western Europe. CURRENT HOLDINGS AND PIPELINE Meneldor has a very exciting pipeline. Details will be shared only under NDA. Our current holdings are: 2016: Xenikos B.V. : Developing a drug therapy in acute Graft vs Host disease to reset the immune system of the donated stem cells 2017: Atriva Therapeutics GmbH: Developing novel, broadly active anti-viral drugs with an excellent benefit-risk profile 2018: Aptamer Group Ltd: Automated-DOE driven aptamer discovery platform for the development of therapeutics and diagnostics 2019: LightOx Ltd: Developing fluorescent drugs that are capable of targeting selected cell types and killing them on illumination with light